Quadrant Capital Group’s Beam Therapeutics BEAM Stock Holding History

Quadrant Capital Group’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-31	Closed	-$606	–	1482
2025 Q1	$606	Hold	31	–	–	﹤0.01%	2636
2024 Q4	$769	Sell	31 -88	-74%	-$2.25K	﹤0.01%	2615
2024 Q3	$2.92K	Hold	119	–	–	﹤0.01%	2433
2024 Q2	$2.79K	Sell	119 -930	-89%	-$22.8K	﹤0.01%	2422
2024 Q1	$34.7K	Sell	1,049 -153	-13%	-$4.77K	﹤0.01%	1585
2023 Q4	$32.7K	Sell	1,202 -128	-10%	-$3.18K	﹤0.01%	1592
2023 Q3	$32K	Buy	+1,330	New	+$35.7K	﹤0.01%	1482
2023 Q1	–	Sell	-44	Closed	-$1.72K	–	2721
2022 Q4	$1.72K	Hold	44	–	–	﹤0.01%	2452
2022 Q3	$2K	Hold	44	–	–	﹤0.01%	2336
2022 Q2	$2K	Buy	+44	New	+$1.75K	﹤0.01%	2181
2021 Q4	–	Sell	-97	Closed	-$8K	–	2512
2021 Q3	$8K	Buy	+97	New	+$9.74K	﹤0.01%	1690

Other funds holding BEAM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

AVM

Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Quadrant Capital Group's BEAM Position: Q2 2025 in Review

Quadrant Capital Group sold out of Beam Therapeutics (BEAM) in Q2 2025, closing a stake of 31 shares — an estimated $606 sold.

Quadrant Capital Group first reported a position in BEAM in Q3 2021 and held it in 11 quarters. The position peaked at $34.7K in Q1 2024. 217 funds tracked by Wall St. Rank hold BEAM as of Q2 2025.

Quadrant Capital Group reported no remaining Beam Therapeutics position as of Q2 2025 after selling out during the quarter.
Quadrant Capital Group sold 31 Beam Therapeutics shares in Q2 2025, an estimated $606.
Quadrant Capital Group first reported a position in Beam Therapeutics in Q3 2021 and held it in 11 quarters.
Quadrant Capital Group's Beam Therapeutics position peaked at $34.7K in Q1 2024.
217 funds tracked by Wall St. Rank held Beam Therapeutics as of Q2 2025.

Based on Quadrant Capital Group's 13F filing for Q2 2025, filed 13 Aug 2025.